niacinamide has been researched along with Chordoma in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Chordoma: A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Additional clinical trials further exploring sorafenib as a treatment of locally advanced or metastatic chordomas are warranted." | 9.20 | Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). ( Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E, 2015) |
| "Chordoma patients were treated with sorafenib 800 mg/day for 9 months, unless earlier occurrence of progression or toxicities." | 7.83 | Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). ( Bertucci, F; Blay, JY; Bompas, E; Camoin, L; Clisant, S; Decoupigny, E; Goncalves, A; Laurence, V; Lebellec, L; Mir, O; Penel, N; Toiron, Y; Tresch-Bruneel, E, 2016) |
| "Additional clinical trials further exploring sorafenib as a treatment of locally advanced or metastatic chordomas are warranted." | 5.20 | Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). ( Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E, 2015) |
| " We describe a case with progressive recurrent chordoma who initially became hyperthyroid in a context of autoimmunity under sorafenib treatment and later under imatinib treatment." | 3.83 | Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. ( Castinetti, F; Eroukhmanoff, J; Penel, N; Salas, S, 2016) |
| "Chordoma patients were treated with sorafenib 800 mg/day for 9 months, unless earlier occurrence of progression or toxicities." | 3.83 | Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). ( Bertucci, F; Blay, JY; Bompas, E; Camoin, L; Clisant, S; Decoupigny, E; Goncalves, A; Laurence, V; Lebellec, L; Mir, O; Penel, N; Toiron, Y; Tresch-Bruneel, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lebellec, L | 3 |
| Chauffert, B | 1 |
| Blay, JY | 3 |
| Le Cesne, A | 2 |
| Chevreau, C | 2 |
| Bompas, E | 3 |
| Bertucci, F | 3 |
| Cupissol, D | 1 |
| Fabbro, M | 1 |
| Saada-Bouzid, E | 2 |
| Duffaud, F | 1 |
| Feuvret, L | 1 |
| Bonneville-Levard, A | 1 |
| Bay, JO | 1 |
| Vauleon, E | 1 |
| Vinceneux, A | 1 |
| Noel, G | 1 |
| Penel, N | 4 |
| Mir, O | 2 |
| Tresch-Bruneel, E | 2 |
| Laurence, V | 2 |
| Collard, O | 1 |
| Isambert, N | 1 |
| Amela, EY | 1 |
| Salas, S | 2 |
| Italiano, A | 1 |
| Clisant, S | 2 |
| Eroukhmanoff, J | 1 |
| Castinetti, F | 1 |
| Toiron, Y | 1 |
| Camoin, L | 1 |
| Decoupigny, E | 1 |
| Goncalves, A | 1 |
| Svoboda, RM | 1 |
| Mackay, D | 1 |
| Welsch, MJ | 1 |
| Anderson, BE | 1 |
1 trial available for niacinamide and Chordoma
| Article | Year |
|---|---|
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chordoma; Female; Follow-Up Studies; France; | 2015 |
4 other studies available for niacinamide and Chordoma
| Article | Year |
|---|---|
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydroc | 2017 |
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.
Topics: Antineoplastic Agents; Chordoma; Graves Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Neopl | 2016 |
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chordoma; Clinical Trials, | 2016 |
Multiple cutaneous metastatic chordomas from the sacrum.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Chordoma; Female; Humans; Niacinamid | 2012 |